2. Search Result
Search Result
Results for "

b0356

" in MedChemExpress (MCE) Product Catalog:

38

Inhibitors & Agonists

2

Biochemical Assay Reagents

1

Peptides

3

Natural
Products

6

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0356
    Ciprofloxacin
    Maximum Cited Publications
    53 Publications Verification

    Bay-09867

    		 Topoisomerase Apoptosis Antibiotic Bacterial Mitochondrial Metabolism Reactive Oxygen Species (ROS) Infection Cancer
    Ciprofloxacin (Bay-09867) is a potent, orally active topoisomerase IV inhibitor. Ciprofloxacin induces mitochondrial DNA and nuclear DNA damage and lead to mitochondrial dysfunction, ROS production. Ciprofloxacin has anti-proliferative activity and induces apoptosis. Ciprofloxacin is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity .
    Ciprofloxacin
  • HY-B0356B
    Ciprofloxacin hydrochloride monohydrate
    50+ Cited Publications

    Bay-09867 hydrochloride monohydrate

    		 Topoisomerase Apoptosis Antibiotic Bacterial Mitochondrial Metabolism Reactive Oxygen Species (ROS) Infection Cancer
    Ciprofloxacin (Bay-09867) hydrochloride monohydrate is a potent, orally active topoisomerase IV inhibitor. Ciprofloxacin hydrochloride monohydrate induces mitochondrial DNA and nuclear DNA damage and lead to mitochondrial dysfunction, ROS production. Ciprofloxacin hydrochloride monohydrate has anti-proliferative activity and induces apoptosis. Ciprofloxacin hydrochloride monohydrate is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity .
    Ciprofloxacin hydrochloride monohydrate
  • HY-B0356A
    Ciprofloxacin monohydrochloride
    50+ Cited Publications

    Bay-09867 monohydrochloride

    		 Topoisomerase Apoptosis Antibiotic Bacterial Mitochondrial Metabolism Reactive Oxygen Species (ROS) Infection Cancer
    Ciprofloxacin (Bay-09867) monohydrochloride is a potent, orally active topoisomerase IV inhibitor. Ciprofloxacin monohydrochloride induces mitochondrial DNA and nuclear DNA damage and lead to mitochondrial dysfunction, ROS production. Ciprofloxacin monohydrochloride has anti-proliferative activity and induces apoptosis. Ciprofloxacin monohydrochloride is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity .
    Ciprofloxacin monohydrochloride
  • HY-B0356S1
    Ciprofloxacin-d8

    Bay-09867-d8

    		 Bacterial Antibiotic Infection
    Ciprofloxacin-d8 is the deuterium labeled Ciprofloxacin. Ciprofloxacin (Bay-09867) is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity.
    Ciprofloxacin-d8
  • HY-B0356S
    Ciprofloxacin-d8 hydrochloride

    Bay-09867-d8 hydrochloride

    		 Bacterial Antibiotic Infection
    Ciprofloxacin-d8 (hydrochloride) is the deuterium labeled Ciprofloxacin. Ciprofloxacin (Bay-09867) hydrochloride is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity.
    Ciprofloxacin-d8 hydrochloride
  • HY-B0356R
    Ciprofloxacin (Standard)

    Bay-09867 (Standard)

    		 Reference Standards Topoisomerase Apoptosis Antibiotic Bacterial Mitochondrial Metabolism Reactive Oxygen Species (ROS) Infection Cancer
    Ciprofloxacin (Standard) is the analytical standard of Ciprofloxacin. This product is intended for research and analytical applications. Ciprofloxacin (Bay-09867) is a potent, orally active topoisomerase IV inhibitor. Ciprofloxacin induces mitochondrial DNA and nuclear DNA damage and lead to mitochondrial dysfunction, ROS production. Ciprofloxacin has anti-proliferative activity and induces apoptosis. Ciprofloxacin is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity .
    Ciprofloxacin (Standard)
  • HY-B0356BR
    Ciprofloxacin hydrochloride monohydrate (Standard)

    Bay-09867 hydrochloride monohydrate (Standard)

    		 Reference Standards Topoisomerase Apoptosis Antibiotic Bacterial Mitochondrial Metabolism Reactive Oxygen Species (ROS) Infection Cancer
    Ciprofloxacin (hydrochloride monohydrate) (Standard) is the analytical standard of Ciprofloxacin (hydrochloride monohydrate). This product is intended for research and analytical applications. Ciprofloxacin (Bay-09867) hydrochloride monohydrate is a potent, orally active topoisomerase IV inhibitor. Ciprofloxacin hydrochloride monohydrate induces mitochondrial DNA and nuclear DNA damage and lead to mitochondrial dysfunction, ROS production. Ciprofloxacin hydrochloride monohydrate has anti-proliferative activity and induces apoptosis. Ciprofloxacin hydrochloride monohydrate is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity .
    Ciprofloxacin hydrochloride monohydrate (Standard)
  • HY-B0356AS
    Ciprofloxacin-d8 hydrochloride hydrate

    Bay-09867-d8 hydrochloride hydrate

    		 Isotope-Labeled Compounds Bacterial Antibiotic Infection
    Ciprofloxacin-d8 (hydrochloride hydrate) is the deuterium labeled Ciprofloxacin hydrochloride monohydrate. Ciprofloxacin hydrochloride monohydrate is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity.
    Ciprofloxacin-d8 hydrochloride hydrate
  • HY-B0356AR
    Ciprofloxacin monohydrochloride (Standard)

    Bay-09867 monohydrochloride (Standard)

    		 Reference Standards Topoisomerase Apoptosis Antibiotic Bacterial Mitochondrial Metabolism Reactive Oxygen Species (ROS) Infection Cancer
    Ciprofloxacin (monohydrochloride) (Standard) is the analytical standard of Ciprofloxacin (monohydrochloride). This product is intended for research and analytical applications. Ciprofloxacin (Bay-09867) monohydrochloride is a potent, orally active topoisomerase IV inhibitor. Ciprofloxacin monohydrochloride induces mitochondrial DNA and nuclear DNA damage and lead to mitochondrial dysfunction, ROS production. Ciprofloxacin monohydrochloride has anti-proliferative activity and induces apoptosis. Ciprofloxacin monohydrochloride is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity [4].
    Ciprofloxacin monohydrochloride (Standard)
  • HY-B0356BS
    Ciprofloxacin-d8 hydrochloride monohydrate

    Bay-09867-d8 hydrochloride monohydrate

    		 Isotope-Labeled Compounds Bacterial Antibiotic Infection
    Ciprofloxacin-d8 (hydrochloride monohydrate) is the deuterium labeled Ciprofloxacin (hydrochloride monohydrate). Ciprofloxacin hydrochloride is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity.
    Ciprofloxacin-d8 hydrochloride monohydrate
  • HY-B0356S2
    Ciprofloxacin-d4

    Bay-09867-d4

    		 Isotope-Labeled Compounds Antibiotic Bacterial Apoptosis Topoisomerase Reactive Oxygen Species (ROS) Mitochondrial Metabolism Infection Cancer
    Ciprofloxacin-d4 (Bay-09867-d4) is deuterium labeled Ciprofloxacin. Ciprofloxacin (Bay-09867) is a potent, orally active topoisomerase IV inhibitor. Ciprofloxacin induces mitochondrial DNA and nuclear DNA damage and lead to mitochondrial dysfunction, ROS production. Ciprofloxacin has anti-proliferative activity and induces apoptosis. Ciprofloxacin is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity .
    Ciprofloxacin-d4
  • HY-B0356AS1
    Ciprofloxacin-13C3,15N monohydrochloride

    Bay-09867-13C3,15N monohydrochloride

    		 Antibiotic Topoisomerase Reactive Oxygen Species (ROS) Bacterial Apoptosis Mitochondrial Metabolism Isotope-Labeled Compounds Infection
    Ciprofloxacin- 13C3, 15N (Bay-09867- 13C3, 15N) monohydrochloride is 13C- and 15N-labeled Ciprofloxacin (monohydrochloride) (HY-B0356A) .
    Ciprofloxacin-13C3,15N monohydrochloride
  • HY-Y1718
    Tridecanoic acid
    1 Publications Verification

    N-Tridecanoic acid

    		 Endogenous Metabolite Bacterial Infection
    Tridecanoic acid (N-Tridecanoic acid) is a medium-chain saturated fatty acid and inhibitor with no antibacterial activity against enterohemorrhagic E. coli (EHEC). When used in combination with Ciprofloxacin (HY-B0356) or Ampicillin (HY-B0522), Tridecanoic acid suppresses persister formation in exponentially growing E. coli and EHEC, but exerts no inhibitory effect on persister formation induced by Kanamycin (HY-16566) or in stationary-phase cells. Tridecanoic acid inhibits biofilm formation in EHEC. It can be used in the research of bacterial infections .
    Tridecanoic acid
  • HY-177716
    Ciprofloxacin prodrug-1

    		Beta-lactamase Bacterial Infection
    Ciprofloxacin prodrug-1 (Compound 35) is an activated prodrug of β-lactase. Ciprofloxacin prodrug-1 exhibits good antibacterial activity against bacteria containing β-lactase (MIC = 63 nM). After being hydrolyzed by β-lactase, Ciprofloxacin prodrug-1 can release Ciprofloxacin (HY-B0356), thereby inhibiting the activity of DNA gyrase. Ciprofloxacin prodrug-1 can be used to study infections caused by enzyme-producing drug-resistant bacteria (such as uropathogenic Escherichia coli) .
    Ciprofloxacin prodrug-1
  • HY-122139
    Desethylene Ciprofloxacin hydrochloride

    		Bacterial Infection
    Desethylene Ciprofloxacin hydrochloride is a major metabolite of Ciprofloxacin (HY-B0356). Ciprofloxacin is an orally active topoisomerase IV inhibitor. Desethylene Ciprofloxacin hydrochloride has antibacterial activity .
    Desethylene Ciprofloxacin hydrochloride
  • HY-W753945
    N‐Nitrosociprofloxacin

    		Drug Intermediate Others
    N‐Nitrosociprofloxacin is a Ciprofloxacin (HY-B0356) impurity.
    N‐Nitrosociprofloxacin
  • HY-N8606
    N-Acetylciprofloxacin

    		Endogenous Metabolite Others
    N-Acetylciprofloxacin is the metabolite of Ciprofloxacin (HY-B0356) .
    N-Acetylciprofloxacin
  • HY-120011
    Ro 24-6392

    		Bacterial Others
    Ro 24-6392 is an ester-linked co-drug combining Ciprofloxacin (HY-B0356) and Desacetylcefotaxime (HY-126129) with inhibitory activity against a variety of aerobic bacteria in vitro.
    Ro 24-6392
  • HY-122139R
    Desethylene Ciprofloxacin hydrochloride (Standard)

    		Bacterial Reference Standards Infection
    Desethylene Ciprofloxacin (hydrochloride) (Standard) is the analytical standard of Desethylene Ciprofloxacin (hydrochloride). This product is intended for research and analytical applications. Desethylene Ciprofloxacin hydrochloride is a major metabolite of Ciprofloxacin (HY-B0356). Ciprofloxacin is an orally active topoisomerase IV inhibitor. Desethylene Ciprofloxacin hydrochloride has antibacterial activity .
    Desethylene Ciprofloxacin hydrochloride (Standard)
  • HY-151944
    Antibacterial agent 128

    		Bacterial Antibiotic Infection
    Antibacterial agent 128 is a siderophore analog-Ciprofloxacin (HY-B0356) conjugate with a cleavable linker. Antibacterial agent 128 shows antibiotic activities against P. aeruginosa (MIC values of 0.25-64 μg/mL) and B. pseudomallei (MIC values of 1-32 μg/mL) .
    Antibacterial agent 128
  • HY-NP0248
    Ciprofloxacin-BSA

    		Biochemical Assay Reagents Inflammation/Immunology
    Ciprofloxacin-BSA is a conjugate of Ciprofloxacin (HY-B0356) and BSA. By conjugating the antigen with protein adjuvants, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt the primary epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells .
    Ciprofloxacin-BSA
  • HY-149333
    BO-1

    		Bacterial Infection
    BO-1 is a benzoate ester with antibacterial activity. BO-1 inhibits multidrug-resistant Staphylococcus aureus, and acts function synergistically with antibiotic, such as Ciprofloxacin (HY-B0356). BO-1 can reverse the resistance of antibiotic-resistant S. aureus strains, and decreases the level of inflammatory factors IL-6 and C-reactive protein in vivo in mice .
    BO-1
  • HY-149881
    Quorum sensing-IN-2

    		Bacterial Infection
    Quorum sensing-IN-2 (compound 23e) is a quorum sensing inhibitor, which can reduce the pathogenicity of bacteria without affecting bacterial growth. Quorum sensing-IN-2 inhibits bacterial infections with little hemolytic activity. Quorum sensing-IN-2 shows synergistic effect with Ciprofloxacin (HY-B0356) in the bacteremia model infected with P. aeruginosa PAO1 .
    Quorum sensing-IN-2
  • HY-168631
    Antibacterial agent 254

    		Bacterial Infection
    Antibacterial agent 254 (Compound 2) is a dispersion sensor (DspS) activator that disperses Pseudomonas aeruginosa biofilms. Antibacterial agent 254 can dislodge 7-day P. aeruginosa biofilms at 50 μM. Antibacterial agent 254 also enhances the effects of Ciprofloxacin (HY-B0356) against P. aeruginosa and increases the expression of matrix-degrading enzyme genes pelA, pslG and eddA .
    Antibacterial agent 254
  • HY-123508
    PD 131628

    		Drug Metabolite Bacterial Infection
    PD 131628 is an antimicrobial agent and active PD 131112 metabolite. PD 131628 is two- to four-fold more active than Ciprofloxacin (HY-B0356), inhibiting all strains of Staphylococcus aureus and Streptococcus pneumoniae. PD 131628 is very active against Neisseria spp., Haemophilus influenzae and Moraxella catarrhalis, with MIC90s ranging from 0.004 to 0.008 mg/L .
    PD 131628
  • HY-155479
    PqsR-IN-3

    		Bacterial Infection
    PqsR-IN-3 (compound 16e) is a selective inhibitor of the pqs system (IC50=3.7 μM) and its associated virulence factor pyocyanin (IC50=2.7 μM). PqsR-IN-3 inhibits bacterial biofilm synthesis and is significantly cytotoxic against Pseudomonas aeruginosa. PqsR-IN-3 has synergistic effects with several antibiotics, such as Ciprofloxacin (HY-B0356) and Tobramycin (HY-B0441) .
    PqsR-IN-3
  • HY-173270
    Antibacterial synergist 3

    		Bacterial Infection
    Antibacterial synergist 3 is a dual-acting inhibitor of biofilm (IC50 of PAO1: 0.40 μM and IC50 of PA14: 1.45 μM). Antibacterial synergist 3 reduces virulence production by inhibiting the quorum sensing (QS) system and induces iron deficiency in P. aeruginosa PAO1. Antibacterial synergist 3 enhances the efficacy of Tobramycin (HY-B0441) and Ciprofloxacin (HY-B0356) in a mouse wound infection model. Antibacterial synergist 3 can be used for the research of P. aeruginosa infections .
    Antibacterial synergist 3
  • HY-163481
    Antibiofilm agent-6

    		Bacterial Infection
    Antibiofilm agent-6 (Compound 26c) is a quorum sensing inhibitor with strong antibiofilm effects that can inhibit the fluorescence intensity of PAO1-lasB-gfp and PAO1-pqsA-gfp in a concentration-dependent manner. Antibiofilm agent-6 can inhibit the production of pyocyanin and rhamnolipid. Antibiofilm agent-6 aids helps ciprofloxacin (HY-B0356) effectively eliminate the living bacteria in a mouse model infected with P. aeruginosa PAO1 .
    Antibiofilm agent-6
  • HY-174326
    Antibacterial agent 282

    		Bacterial Infection
    Antibacterial agent 282 (Compound CP7), a seleno-Ciprofloxacin (HY-B0356) derivative, is an Antibacterial agent. Antibacterial agent 282 has significant antibacterial activity against gram-positive bacterium and gram-negative bacterium with MICs of 0.1-1.56 and 0.1-3.13 μg/mL, respectively (MBCs of 0.2-1.56 and 0.39-12.5 μg/mL). Antibacterial agent 282 potently disrupts and prevents biofilms formation of P. aeruginosa. Antibacterial agent 282 shows significant inhibitory activity towards the DNA gyrase from E. coli .
    Antibacterial agent 282
  • HY-180128
    OXF-077

    		Bacterial Infection
    OXF-077 is a potent SOS response inhibitor with an IC50 of 1.2 µM against Ciprofloxacin (HY-B0356)-activated SOS response. OXF-077 targets SpsB. OXF-077 suppresses the emergence of Ciprofloxacin resistance in Staphylococcus aureus .
    OXF-077
  • HY-NP0248A
    Ciprofloxacin-OVA

    		Biochemical Assay Reagents Inflammation/Immunology
    Ciprofloxacin-OVA is a conjugate of Ciprofloxacin (HY-B0356) and Ovalbumin (OVA). By conjugating the antigen with protein adjuvants, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt the primary epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells .
    Ciprofloxacin-OVA
  • HY-183712
    Antibacterial agent 345

    		Bacterial DNA/RNA Synthesis Drug Derivative Infection
    Antibacterial agent 345 is a Ciprofloxacin (HY-B0356)-lipophilic derivative and is an antibacterial agent. Antibacterial agent 345 inhibits DNA gyrase and inhibits bacterial DNA replication and transcription. Antibacterial agent 345 inhibits bacterial biofilm formation. Antibacterial agent 345 can be used for the research of bacterial infections, such as Pseudomonas aeruginosa infection .
    Antibacterial agent 345
  • HY-181935
    Antibiotic adjuvant 4

    		Bacterial Infection
    Antibiotic adjuvant 4 (Compound 13) is an Antibiotic adjuvant and efflux pump inhibitor. Antibiotic adjuvant 4 exhibits potent efflux pump inhibitory activity. Antibiotic adjuvant 4 significantly downregulates virulence-related genes of Staphylococcus aureus when used alone or in combination with antibiotics. Antibiotic adjuvant 4 enhances the efficacy of Ciprofloxacin (HY-B0356) against multiagent-resistant Staphylococcus aureus strains .
    Antibiotic adjuvant 4
  • HY-126258
    IMP-1700

    		Bacterial DNA/RNA Synthesis Infection
    IMP-1700 is a potent DNA damage potentiator and antibacterial agent. IMP-1700 inhibits the bacterial SOS response to DNA damage. IMP-1700 potently sensitizes MRSA to Ciprofloxacin (HY-B0356) with an EC50 of 5.9 nM. IMP-1700 inhibits the growth of E. coli K-12 BW25113, S. aureus SH1000 and MRSA USA300 JE2 .
    IMP-1700
  • HY-183711
    Antibacterial agent 344

    		Bacterial Heme Oxygenase (HO) Infection
    Antibacterial agent 344 is an antibacterial agent with potent biofilm inhibition (IC50 = 0.27 μM). Antibacterial agent 344 inhibits heme oxygenase (HemO), impairs iron homeostasis, virulence factor production, and motility. Antibacterial agent 344 synergizes with Ciprofloxacin (HY-B0356) and Tobramycin (HY-B0441), enhancing their efficacy and delaying the development of resistance. Antibacterial agent 344 improves bacterial-infected Galleria mellonella survival, and reduces bacterial load in mice wounds. Antibacterial agent 344 can be used for the research of Pseudomonas aeruginosa infections .
    Antibacterial agent 344
  • HY-181966
    Sideromycin 7

    		Bacterial DNA/RNA Synthesis Potassium Channel Infection
    Sideromycin 7 is an antibacterial agent. Sideromycin 7 forms a 7-Bi 3+ coordination complex with bismuth citrate, exerting a three-pronged antibacterial mode of action: direct DNA binding to induce damage and arrest replication, suppression of KdpC synthesis to block KdpFABC-mediated potas-sium transport, and inhibition of ATP production. Sideromycin 7 exhibits potent antibacterial activity against Ciprofloxacin (HY-B0356)-resistant Pseudomonas aeruginosa strains. Sideromycin 7 exerts antibiofilm activity against Pseudomonas aeruginosa. Sideromycin 7 can be used for the research of ciprofloxacin-resistant Pseudomonas aeruginosa infection .
    Sideromycin 7
  • HY-N18102
    3,4-Seco-mansumbinoic acid

    		Bacterial Infection
    3,4-Seco-mansumbinoic acid (Compound 2) is an Antibacterial agent. 3,4-Seco-mansumbinoic acid can be isolated from the oleo-resin of Commiphora molmol. 3,4-Seco-mansumbinoic acid exhibits in vitro anti-staphylococcal activity, with the strongest activity against the multidrug-resistant Staphylococcus aureus strain SA-1199B (MIC 4 μg/mL) 3,4-Seco-mansumbinoic acid displays weak potentiation of Ciprofloxacin (HY-B0356) and Tetracycline (HY-A0107) activity against strains of Salmonella enterica serovar Typhimurium SL1344 and L10. 3,4-Seco-mansumbinoic acid can be used for the research of multidrug-resistant bacterial infection (Staphylococcus aureus, Salmonella enterica serovar Typhimurium) .
    3,4-Seco-mansumbinoic acid
  • HY-P11615
    FuK

    		Bacterial Infection
    FuK is a WK2-analog antimicrobial peptide modified with fluorinated unnatural amino acids. FuK has an LD50 of 72.34 mg/kg in mice, shows no hemolytic activity, with high stability against trypsin, chymotrypsin, and saline environments. FuK exerts bactericidal effects by enhancing the permeability of bacterial outer membranes, inducing depolarization of cytoplasmic membranes, and disrupting membrane potential balance against bacterias such as Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, and MRSA. FuK exhibits synergistic antimicrobial activity with polymyxin B (HY-149179), vancomycin (HY-B0671), and ciprofloxacin (HY-B0356), and also inhibits Ciprofloxacin-induced bacterial drug resistance. FuK has in vivo safety, effectively reduces bacterial load and inflammatory cell infiltration in a mouse MRSA model, and promotes collagen fiber formation in skin wounds .
    FuK

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: